SCHEMBL4927205

SCHEMBL4927205

COc1nc2cc(C)ccc2nc1NC(=O)N1CCN(c2ccc(C(C)=O)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.56
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 1/20 0.48
POLB P06746 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 2/20 0.47
THRB P10828 1/20 0.46
MAPK1 P28482 1/20 0.46
PANK3 Q9H999 1/20 0.46
MLLT1 Q03111 1/20 0.45
HTT P42858 1/20 0.43
JAK2 O60674 2/20 0.42
FLT3 P36888 2/20 0.42
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1138244 1.00 MAPT (0.56) MAPTALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL1138412 0.90 MAPT (0.48) MAPTALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL4929561 0.90 MAPT (0.48) MAPTALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL4917704 0.90 MAPT (0.51) MAPTALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL1138455 0.90 MAPT (0.51) MAPTALDH1A1KMT2ASMN1; SMN2KDM4E
SCHEMBL1138769 0.90 MAPT (0.58) MAPTALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL4917906 0.90 SMN1; SMN2 (0.57) MAPTALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL1138087 0.90 SMN1; SMN2 (0.57) MAPTALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL4922702 0.90 MAPT (0.58) MAPTALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL4922301 0.89 MAPT (0.53) MAPTALDH1A1KMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598173-B2 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2013-12-03 US disclosed
US-20130053390-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES REXAHN PHARMACEUTICALS, INC. 2013-02-28 US disclosed
US-8314100-B2 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
US-20080318963-A1 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives REXAHN PHARMACEUTICALS, INC. (US) 2008-12-25 US disclosed
EP-1819698-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES Rexahn Pharmaceuticals, Inc. (US) 2007-08-22 EP disclosed
WO-2006054830-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES REXAHN PHARMACEUTICALS, INC. (US) 2006-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318963-A1 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives HRAS, CDK4, KRAS MAPT 4614/4885ALDH1A1 1028/4885KMT2A 549/4885
US-20130053390-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES HRAS, CDK4, KRAS MAPT 4577/4885ALDH1A1 663/4885KMT2A 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.